In vivo selection of autologous MGMT gene-modified cells following reduced-intensity conditioning with BCNU and temozolomide in the dog model

JL Gori1, BC Beard1,2, C Ironside1, G Karponi1 and H-P Kiem1,2

Chemotherapy with 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) and temozolomide (TMZ) is commonly used for the treatment of glioblastoma multiforme (GBM) and other cancers. In preparation for a clinical gene therapy study in patients with glioblastoma, we wished to study whether these reagents could be used as a reduced-intensity conditioning regimen for autologous transplantation of gene-modified cells. We used an MGMT(P140K)-expressing lentivirus vector to modify dog CD34+ cells and tested in four dogs whether these autologous cells engraft and provide chemoprotection after transplantation. Treatment with O6-benzylguanine (O6BG)/TMZ after transplantation resulted in gene marking levels up to 75%, without significant hematopoietic cytopenia, which is consistent with hematopoietic chemoprotection. Retrovirus integration analysis showed that multiple clones contribute to hematopoiesis. These studies demonstrate the ability to achieve stable engraftment of MGMT(P140K)-modified autologous hematopoietic stem cells (HSCs) after a novel reduced-intensity conditioning protocol using a combination of BCNU and TMZ. Furthermore, we show that MGMT(P140K)-HSC engraftment provides chemoprotection during TMZ dose escalation. Clinically, chemoconditioning with BCNU and TMZ should facilitate engraftment of MGMT(P140K)-modified cells while providing antitumor activity for patients with poor prognosis glioblastoma or alkylating agent-sensitive tumors, thereby supporting dose-intensified chemotherapy regimens.

Cancer Gene Therapy (2012) 19, 523--529; doi:10.1038/cgt.2012.25; published online 25 May 2012

Keywords: hematopoietic stem cells; conditioning regimens; glioblastoma

INTRODUCTION

Successful transfer of chemotherapy resistance genes into hematopoietic stem cells (HSCs) holds tremendous therapeutic promise for patients with malignancies by conferring myeloprotection during chemotherapy and allowing for dose-intensified chemotherapy regimens and/or combination chemotherapy to maximize the antitumor effect. The level of myeloprotection directly correlates with the level of gene-modified cell engraftment (for review see Neff et al1). In order to improve HSC engraftment and chemoprotection, ex vivo gene transfer protocols and conditioning regimens must be optimized. Genetic modification of HSCs with retroviral vectors has progressed to the point at which stable, long-term engraftment of modified cells and therapeutic levels of transgene expression are routinely achieved in large-animal models2,3 and clinical applications.4--7 Therapeutic gene expression levels are augmented when the cells have an inherent selective survival or growth advantage5--7 or by conditioning with myeloblastic doses of radiation or chemical agents such as cyclophosphamide and busulfan.8--11 Under circumstances in which the incoming graft does not have a growth advantage, conditioning with myeloblastic radiation or high-dose chemotherapy may be required to achieve a clinically beneficial level of gene marking.

In the setting of genetic disease in which the gene-modified cells provide an alternative or experimental treatment option, an aggressive conditioning regimen is not easily justified, despite the potential therapeutic benefit, as it deviates from the traditional standard of care and increases the risk of toxicity to the patient. Candidate patients for HSC gene therapy, who present with serious medical comorbidities, may not be able to tolerate myeloablative conditioning with DNA-damaging agents. Such patients may therefore require a reduced-intensity conditioning regimen to achieve gene-modified cell engraftment. Studies in large animals and in patients demonstrate that reduced-intensity conditioning decreases the severity of myelosuppression and time to hematopoietic recovery.12,13 Although reduced-intensity conditioning with busulfan14 and cyclophosphamide15 extends HSC transplantation to patients who would otherwise be ineligible, novel disease-specific chemical regimens that simultaneously condition for transplantation and have an antitumor effect are needed.16 To address this in the context of malignant disease, a more aggressive conditioning regimen with a disease-specific chemotherapeutic is appropriate, provided that the conditioning regimen is tailored to provide both a potent antitumor effect and sufficient myelosuppression to support engraftment of gene-modified cells. In preparation for a clinical trial for patients with glioblastoma multiforme (GBM), the goal of the studies described herein is to test a clinically relevant conditioning regimen in a large-animal model that meets the following criteria: (1) documented HSC toxicity17,18 to facilitate engraftment of MGMT(P140K) gene-modified cells, (2) reduced extramedullary toxicity and (3) a documented antiglioma effect.19--22
Temozolomide (TMZ) and 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) are frequently used to treat GBM, the most common subtype of primary brain tumors in adults and children; however, even with aggressive treatment, median survival after diagnosis is ~12 months.\textsuperscript{3,24} Chemotherapy with BCNU, methylation agents (procarbazine or TMZ) or other agents is effective and can prolong survival. Phase I and II clinical trials have shown that the combination of BCNU and TMZ results in a partial response in tumor regression in patients suffering from glioblastoma, while establishing the maximum tolerated doses as combination neoadjuvant therapy.\textsuperscript{13,25} However, the benefit of prolonging survival is attenuated by the hematopoietic toxicity of chemotherapy agents like BCNU and TMZ, which prevents chemotherapy dose escalation. In addition, a subset of patients with glioblastoma who exhibit high levels of MGMT expression would greatly benefit from the addition of the wild-type MGMT inhibitor O\textsubscript{6}-benzylguanine (O6BG). Although the addition of O6BG to the alkylating agent from the addition of the wild-type MGMT inhibitor O\textsubscript{6}-benzylguanine (O6BG). Although the addition of O6BG to the alkylating agent would not only prevent MGMT-mediated O\textsubscript{6}-methylguanine excision repair, but also enhance BCNU-mediated cytotoxicity, the drug combination exacerbates hematopoietic toxicity.\textsuperscript{26–28}

To assess the extent of chemoprotection provided by drug resistance gene therapy for glioblastoma patients and to alleviate pancytopenia due to combinations of O6BG and TMZ or BCNU, we previously evaluated engraftment and in vivo selection/chemoprotection of MGMT(P140K)-modified HSCs in clinically relevant dog and monkey models. These studies demonstrated that MGMT(P140K)-HSC engraftment leads to effective multilineage in vivo selection and chemoprotection.\textsuperscript{21,29,30} As an extension of these findings, the goal of the current autologous transplantation study in dogs is to evaluate a novel reduced-intensity conditioning regimen with BCNU or TMZ, this drug combination exacerbates hematopoietic toxicity.\textsuperscript{26–28}

**MATERIALS AND METHODS**

**Animals**

Dogs were raised and housed at the Fred Hutchinson Cancer Research Center under conditions approved by the American Association for Accreditation of Laboratory Animal Care. Animal experiments were reviewed and approved by the Fred Hutchinson Cancer Research Institutional Animal Care and Use Committee. For CD34 mobilization and priming, dogs were treated with canine stem cell factor (25 μg·kg\textsuperscript{-1} body weight subcutaneously, once daily) and canine granulocyte-colony stimulating factor (5 μg·kg\textsuperscript{-1} body weight subcutaneously, twice daily) for 4 consecutive days. CD34\textsuperscript{+} cells were then isolated from leukapheresis or bone marrow products using established methods.

**Lentivirus vectors**

The self-inactivating (SIN) lentivirus vector WPT-P140K contains the short form of the elongation factor-\textsuperscript{1\alpha} (EF1\textsubscript{\alpha}) promoter expressing MGMT(P140K) transgene with the WPRE (described above), and was kindly provided by Dr Stanton Gerson. The lentivirus vector RSCEMv2 was generated by excising the EF1\textsubscript{\alpha}-MGMT(P140K) (EM) cassette from the WPT-P140K backbone with Xhol and ligated upstream of the phosphoglycerate kinase promoter (PGK) yellow fluorescent protein (YFP) cassette, and WPRE in the RRL lentivirus backbone (described in Horn et al\textsuperscript{17}) that had been linearized with Xhol. After in vitro testing for MGMT(P140K)-mediated selection, the PGK-YFP cassette was excised with XcmI and BsrGI, end-polished with T4 polymerase and ligated. Elimination of the PGK-YFP cassette was confirmed by sequencing. The WPT\textsubscript{\alpha}-P140K vector was generated by excising the EF1\textsubscript{\alpha} promoter with Clal and BamHI, end polishing with T4 polymerase and ligation of the backbone. Elimination of the EF1\textsubscript{\alpha} promoter from WPT\textsubscript{\alpha}-P140K was confirmed by sequencing. Vector stocks were generated by transient transfection, concentrated, and titered, as previously described.\textsuperscript{31}

**Dog CD34 + cell isolation and transduction**

The method has been described previously.\textsuperscript{32–33} Briefly, peripheral blood or bone marrow cells were labeled with biotinylated monoclonal antibody 1H6 at 4°C for 30 min. The cells were washed twice, incubated with streptavidin-conjugated microbeads for 30 min at 4°C, washed again and then separated by means of an immunomagnetic column technique (Miltenyi Biotec, Auburn, CA) according to the manufacturer’s instructions. In the instances where CD34-selected cells were prestimulated (see Table 1), cells were cultured in Isocove’s modified Dulbecco’s medium supplemented with 10% fetal bovine serum (Gibco BRL, Gaithersburg, MD), supplemented with 10% fetal bovine serum (Gibco BRL, Gaithersburg, MD),

**Table 1.** Conditioning chemotherapy, retroviral vectors, transduction conditions and engraftment

| Dog   | Conditioning regimen | Vector | Transduction (total MOI) | Initial gene transfer (% by Q-PCR) | Cells infused × 10\textsuperscript{6} per kg | Days ANC < 100 per μl | Day of initial gene marking assessment | Initial gene marking (% by Q-PCR) |
|-------|----------------------|--------|--------------------------|----------------------------------|-------------------------------------------|-----------------------|----------------------------------------|----------------------------------|
| G547  | BCNU 50/550          | WPT-P140K | 24 h prestimulation, 4h+ON (37 × 2) | 66.3                             | 19.2                                      | 1                     | 41                                      | 2.8                              |
| G834  | BCNU 50/550          | WPT-P140K | No prestimulation, ON (10)      | 12.8                             | 1.5                                       | 4                     | 35                                      | 0.7                              |
| G867  | BCNU 50/550          | WPT-P140K | No prestimulation, ON (10)      | 33.5                             | 3.8                                       | 6                     | 32                                      | 1.2                              |
| G593  | BCNU 30/850          | WPT-P140K | 24 h prestimulation, 4h × 2 (25 × 2) | 62                              | 6.2                                       | 4                     | 27                                      | 2.1                              |
| G580  | BCNU 30/700          | WPT-P140K/ | 24h, 48 h\textsuperscript{b} | 65/45                            | 16.5/20                           | 2                     | 46                                      | 5.5                              |

Abbreviations: ANC, absolute neutrophil count; BCNU, 1,3-bis (2-chloroethyl)-1-nitrosourea; MOI, multiplicity of infection; ON, overnight; Q-PCR, quantitative PCR; TMZ, temozolomide.

\textsuperscript{a}CD34\textsuperscript{+} cells collected from apheresis product.

\textsuperscript{b}CD34\textsuperscript{+} cells collected from bone marrow.

\textsuperscript{c}Initial gene marking (% by Q-PCR) is reported from the day of the first post-transplant chemotherapy or the closest time point just before treatment, which is the date indicated in column entitled ‘Day of initial gene marking assessment’. The values for the dog that never received post-transplant chemotherapy (G580) are reported from ~3 weeks following transplantation.
1% penicillin/streptomycin (Gibco, BRL) in the presence of canine granulocyte-colony stimulating factor, canine stem cell factor and human Flt3-ligand, each at 50 ng ml⁻¹; CD34⁺ cells were then exposed to lentivirus vector virus-conditioned media at a multiplicity of infection indicated in Table 1 in 75 cm² non-TC treated flasks (Corning, Corning, NY) coated with CH-296 (Retronectin; Takara Shuzo, Otsu, Japan) at a concentration of 2 μg cm⁻². Culture medium is the same noted above with the additional supplement of protamine sulfate (8 μg ml⁻¹). Flow-through cells were stored at 4°C for the duration of the procedure. Following the last exposure to virus-conditioned media, nonadherent and adherent cells were pooled, counted and prepared for infusion. Both transduced and nontransduced cells were reinfused intravenously into the original donor (autologous) dog at least 24 h after BCNU and TMZ administration.

Conditioning with BCNU and TMZ

The maximum tolerated dose of BCNU and TMZ in combination (no pretreatment with O6BG) is 150 and 550 mg m⁻², respectively. Based on data from our lab and personal communications with Eileen Dolan (University of Chicago) that dogs are ~2–3 times more sensitive to BCNU than humans, we adjusted the conditioning dose of BCNU accordingly. To account for this difference in drug sensitivity, we treated with a chemical conditioning protocol of 30–50 mg m⁻² BCNU and 550–850 mg m⁻² TMZ as outlined in Table 1. As preparation for transplantation, the animals received a single dose of BCNU (Bristol-Myers Squibb, Princeton, NJ) and TMZ (Schering-Plough, Kenilworth, NJ) (Table 1). BCNU was diluted according to the manufacturer’s instructions and was further diluted in normal saline to a total volume of 18 ml and infused over ~4 min, followed 2 h later by p.o. administration of TMZ. Post-transplantation conditioning support

Quantitative PCR (TaqMan)

Relative gene marking levels with the vector in total bone marrow and white blood cells were analyzed with the TaqMan 5' nuclease quantitative real-time (Q)-PCR assay. The gene marking percentages were calculated based on the assumption that the marrow and peripheral blood cells contain one copy of the corresponding vector per cell. Genomic DNA (300 ng) from each dog was amplified in duplicate with a lentivirus-specific primer/probe combination (5'-TGAAGGCAAAAAGGARACCA-3', 5'-CCGTGCGGCGCTCGA-3'; probe: 5'-AGCTCTCGACGGACGACTGCGG-3'). A dog interleukin-3-specific primer/probe combination (5'-ATGAG CAGCTTCCCTTATCATCC-3', 5'-GTGCAAGAAAAGGCTTCC-3'; probe: 5'-FAM-TCTCTGGATGCCGCAAGTCCAC-TAMRA-3') was used to adjust for equal loading of genomic DNA per reaction. Standards consisted of dilutions of DNA extracted from cell lines transduced with a single copy of a lentiviral vector and DNA from a normal dog. Samples were mixed with ABI master mix (Applied Biosystems, Branchburg, NJ) and reactions run on the ABI Prism 7500 sequence detection systems (Applied Biosystems) under the following thermal cycling conditions: 50°C for 2 min and 95°C for 10 min, then 40 cycles of 95°C for 15 s and 60°C for 1 min. Following Q-PCR, samples were plotted against the cell line standards and the percentage of gene marking was calculated from provirus copy number making the assumption that each clone has only a single provirus copy, and hence as an example, 0.1 provirus copies equal 10% gene marking.

Post-transplantation O6BG/TMZ treatment

O6BG (50 mg: Sigma Aldrich, St Louis, MO) was dissolved in 30 ml of 40% polyethylene glycol in phosphate buffered saline, and the concentration was adjusted to 1 mg ml⁻¹ with prewarmed (37°C) phosphate-buffered saline. The drug was further diluted in normal saline to a final volume of 150 ml and was infused over 15 min. BCNU (Bristol-Myers Squibb) was diluted according to the manufacturer’s instructions and was further diluted in normal saline to a total volume of 18 ml. Immediately after administration of O6BG, TMZ was given p.o. at the appropriate dose based on animal surface area calculations. The O6BG dose was fixed throughout the course of the study at 5 mg kg⁻¹, with a maximum of 50 mg per administration. TMZ doses ranged between 600 and 700 mg m⁻².

Colony-forming unit assay

Bone marrow for colony-forming units (CFUs) was isolated, grown in twolayer soft agar and DNA was isolated from individual CFUs as previously described.³

CFU retrovirus-specific PCR

To determine the level of gene marking in bone marrow-derived CFUs, DNA was amplified to detect provirus sequences and overall DNA as previously described.³

Linear amplification-mediated PCR

Retrovirus integration site analysis by linear amplification-mediated (LAM)-PCR was performed on dog DNA isolated from peripheral blood leukocytes as previously described.³

RESULTS

Reduced-intensity conditioning with BCNU and TMZ is well tolerated in dogs

Both BCNU and TMZ are extensively used in the treatment of patients with brain tumors, and BCNU is also widely used for other malignancies like lymphoma. Thus, in preparation for a clinical study using chemoprotected hematopoietic cells in patients with glioblastoma, the goal of these studies is to examine whether the combination of BCNU and TMZ would allow for efficient engraftment of gene-modified cells. In this study, we show that a novel reduced-intensity conditioning regimen with BCNU and TMZ is well tolerated in the clinically relevant dog model of gene-modified drug-resistant autologous HSC transplantation. Based on published clinical data in patients with glioblastoma, we evaluated the combination of BCNU, followed by TMZ for pretransplant conditioning. The maximum tolerated dose of BCNU and TMZ in combination (no pretreatment with O6BG) is 150 and 550 mg m⁻², respectively. Given that dogs exhibit 2- to 3-fold higher chemosensitivity to alkylating agents compared with human patients (unpublished data and personal communications with Eileen Dolan), we adjusted the dose of BCNU to reflect these differences. Before transplantation, dogs received single treatments of intravenous BCNU (30–50 mg m⁻²) and oral (p.o.) TMZ (550–850 mg m⁻²). Dogs received granulocyte-colony stimulating factor (5 μg kg⁻¹ intravenously twice a day b.i.d.) for up to 18 days to facilitate neutrophil recovery after gene-modified HSC transplantation. Based on

Sustained in vivo selection and chemoprotection after stable engraftment and repopulation of MGMT(P140K)-modified hematopoietic cells

In this study, we wanted to determine whether MGMT(P140K) gene-modified hematopoietic cells infused after reduced-intensity conditioning support in vivo selection and provide protection from
post-transplantation chemotherapy. Following transplantation and once peripheral blood counts recovered to levels within the normal range (absolute neutrophil count >1000 cells per μl, platelet count >100 000 cells per μl), dogs were treated with two to four cycles of O6BG (5 mg kg⁻¹) and TMZ (600–700 mg m⁻²). Despite transient decreases in peripheral blood counts following each chemotherapy cycle, the dogs showed marking-dependent chemoprotection from TMZ-induced myelotoxicity (Figure 1). All dogs exhibited long-term gene marking that supported in vivo selection after post-transplantation treatment with O6BG/TMZ (Table 1 and Figure 1). Q-PCR analysis for detection of proviral integrants showed that multiple cycles of O6BG plus TMZ increased gene marking 15- to 250-fold, compared with gene marking observed in white blood cells before chemotherapy (Figures 1 and 2a). To verify high gene marking observed in white blood cells from dog G547, bone marrow was also collected, CFUs plated and then provirus-specific PCR performed on individual bone marrow-derived CFUs on day 90 after transplantation and two cycles of O6BG/TMZ. The high-level gene marking in peripheral blood was confirmed in bone marrow samples, with 71% of the CFUs scored as provirus positive. This level of gene marking is similar to that calculated using Q-PCR at the same time point, 90.4%, and indicates ~1.3 provirus copies per clone.

Whereas gene marking in dogs G547 and G867 increased to levels approaching 100% after 2 to 3 treatments with O6BG and TMZ, G547 was also chemoprotected from myelotoxicity, as platelet and neutrophil counts did not fall significantly below 100 000 cells per μl and 1000 cells per μl after chemotherapy treatment, respectively (Figure 1, black vertical arrow). In addition, whereas a single treatment of O6BG/TMZ led to a transient decrease in neutrophil and platelet counts, gene marking increased from 2.8 to 58.3%. When the dog was treated with a second cycle of an identical dose of O6BG/TMZ after an increase in gene-modified cells, no significant myelosuppression was observed (Figure 1, dog G547). These data provide evidence to suggest that a single treatment of O6BG/TMZ may support in vivo selection to increase the proportion of chemoresistant hematopoietic cells, which then provide bona fide chemoprotection to the transplant recipient. Furthermore, in vivo selection and chemoprotection were achieved within the context of CD34⁺ cell transplantation following nonmyeloablative reduced-intensity conditioning with BCNU and TMZ. LAM-PCR analysis of retroviral insertion sites confirmed polyclonal repopulation was achieved in all dogs analyzed that received reduced-intensity conditioning and gene-modified hematopoietic cell transplantation (Figure 2b and data not shown).

Differential engraftment of promoterless and transcriptionally regulated human MGMT(P140K) gene-modified cells

Long-term engraftment of gene-modified cells was achieved in three of the four animals transplanted with MGMT(P140K)-transduced CD34⁺ cells (Figure 1 and data not shown). However, gene marking in dog G593 decreased after cessation of CSP treatment on day 100 (Figure 2a). Although LAM-PCR results revealed multiple clone repopulation before day 100, a stable selective effect was not achieved in vivo, despite multiple cycles of O6BG and TMZ (Figure 2b). To determine whether the loss of gene-modified cells could be influenced by an immune response to the human variant of MGMT(P140K) transgene expression, a

**Figure 1.** Hematopoietic reconstitution, gene marking and in vivo selection in dogs after reduced-intensity alkylating-based conditioning and transplantation with MGMT(P140K) gene-modified cells. Absolute platelet (○) and neutrophil (●) counts in all dogs transplanted with autologous gene-modified cells after preconditioning chemotherapy. Small black arrows denote post-transplantation O6-benzylguanine (O6BG) and temozolomide (TMZ) administration. Upper and lower gray horizontal lines correspond to lower threshold of platelet counts and absolute neutrophil counts, respectively. In vivo selection of MGMT(P140K) gene marking (△) in white blood cells (WBCs) during the first 120 days after transplantation as determined by quantitative real-time (Q)-PCR analysis. The dogs were treated with two to four cycles of O6BG (5 mg kg⁻¹) and TMZ (600–700 mg m⁻²).
competitive repopulation assay was established in dog G580. G580 was infused with CD34+ transduced with a lentivirus vector containing human MGMT(P140K) with (WPT-P140K) or without (WPTaD-P140K) the human EF1α promoter (Figure 2c). Differential PCR analysis, which amplifies the region flanking the EF1α promoter, showed that detection of the PCR product corresponding to MGMT(P140K) promoter-containing and promoterless proviruses was qualitatively similar in both arms 30 days after transplantation. The PCR product specific for the promoterless MGMT(P140K) provirus was detectable out to 123 days after transplantation, despite CSP cessation. In contrast, the WPT-P140K PCR product band intensity decreased over time and was not detectable after CSP removal. Consistent with the PCR data, MGMT(P140K) marking by Q-PCR, which detects both MGMT-expressing and nonexpressing populations, decreased gradually during the first 2 months after transplantation, stabilizing around 1% (Figure 2d and Supplementary Figure 1). These data imply that following reduced-intensity transplantation, expression of the human MGMT(P140K) in dogs may lead to loss of the gene-modified cells over time, possibly because of other factors including failure to transduce long-term repopulating HSCs, toxicity associated with transgene overexpression, failure of highly marked HSCs to differentiate or an immune response to gene-modified cells. Based on our ongoing studies in patients with glioblastoma, we do not believe that there are immune responses to the human MGMT(P140K) in patients.

**DISCUSSION**

Here we show that a reduced-intensity conditioning regimen based on BCNU and TMZ was well tolerated and allowed for efficient engraftment of autologous hematopoietic repopulating cells genetically modified with a lentivirus vector to express MGMT(P140K). We show in this clinically relevant dog model that multiple clones engrafted and contributed to hematopoiesis and that gene-modified cell engraftment resulted in multilineage chemoprotection proportional to the level of gene marking.

Historically, conditioning regimens for patients enrolled in clinical trials using gene-modified hematopoietic cells have been tailored to minimize myelosuppression to reduce the risk to the patient. Therapeutic benefit in these clinical trials has been aided by at least some modest lineage-specific selective growth advantage of the gene-modified cells (for review, see Fischer et al.34) following conditioning with reduced-intensity busulfan for ADA-SCID,35 CGD36 and WAS36 or without any conditioning for SCID-X1.7 More recently, a successful clinical trial using gene-modified hematopoietic cells for adrenoleukodystrophy used a more aggressive ablative conditioning regimen consisting of cyclophosphamide and busulfan because a relative high level of gene marking was required for therapeutic benefit, and the gene-modified cells do not have an intrinsic growth advantage.4 This latter example is a more appropriate comparison for therapeutic chemoprotection of gene-modified hematopoietic cells in the context of malignant disease. Collectively, these gene therapy clinical trials highlight the importance of tailoring a conditioning regimen and gene transfer strategy that fit best with the patient's disease status and the desired therapeutic risk/benefit ratio. Although appropriate for gene correction studies, the lack of documented antitumor affects associated with busulfan and cyclophosphamide may not be clinically relevant for drug resistance gene therapy applications in the context of malignancies. Here, we took this into consideration and developed a
reduced-intensity conditioning regimen that would also provide a disease-specific antitumor effect for patients with malignant disease where alkylating agents (that is, BCNU and TMZ) would be standard of care chemotherapy.

The primary goal of chemotherapy resistance gene therapy within the context of patients suffering from malignant disease is to protect the hematopoietic system from chemotherapy-associated dose-limiting hematologic toxicity to allow for increased dose intensity and maximize antitumor effect. In order to achieve this goal, each chemosensitive solid tumor malignancy must be evaluated within the framework of the specific chemotherapy resistance genes and treatment regimens. We focused on evaluating a reduced-intensity conditioning regimen to support antitumor activity and engraftment of drug-resistance gene-modified hematopoietic cells directed for the treatment of GBM.

To this end, dogs were conditioned with a combination of TMZ and BCNU and subsequently transplanted with MGMT(P140K) gene-modified cells, delivered by a lentiviral vector. The reduced-intensity conditioning was well tolerated and supported long-term engraftment of gene-modified cells and supported in vivo selection that provided progressively more durable chemoprotection from subsequent doses of O6BG/TMZ combination chemotherapy. Effective engraftment of MGMT(P140K) gene-modified cells that led to successful in vivo selection and chemoprotection was achieved with a relatively short ex vivo transduction protocol using lentivirus vectors. This could be because of a variety of factors included but not limited to improved maintenance of HSC repopulation capacity, improved initial HSC gene transfer levels or a combination of both.

Relative to historical control dogs, the experimental dogs in this study that received MGMT(P140K) lentivirus-transduced cells were protected from pronounced myelosuppression attributed to post-transplant chemotherapy when gene marking levels were >40%, as the extent of chemoprotection is directly proportional to the level of gene marking. Although the initial gene marking level is lower compared with the animals that received myeloablative preconditioning, we are able to approach the higher gene marking levels through in vivo selection. Importantly, LAM-PCR analysis confirmed repopulation of the hematopoietic system by multiple clones. We also found that loss of expression of the human variant of MGMT(P140K) in some dogs coincided with the cessation of immunosuppressive therapy (CSP), which indicates loss of the gene-modified cell population. Although we cannot conclusively attribute loss of the gene-modified graft to an immune response against the human transgene, it is important to consider use of species-specific, optimized transgenes and vectors to improve the likelihood of long-term stable in vivo gene expression.

In addition, these studies provide an important proof-of-concept platform for identifying appropriate reduced-intensity conditioning regimens coupled to specific drug resistance gene transfer for the treatment of other malignancies. This model may be translated to improve outcome in patients with hematopoietic malignancies following relapse, by coupling conditioning with high-dose cytosine arabinoside to infusion of bone marrow gene-modified to express cytidine deaminase, thereby combining chemoprotection of allogeneic cells from post-transplant cytotoxic arabinoside with a graft-versus-leukemia/lymphoma effect. With respect to multidrug resistance gene-1 (MDR1) gene transfer, chemotherapy regimens (vinblastine, colchicine, doxorubicin, paclitaxel) traditionally used to treat MDR1-expressing chemoresistant solid tumors (that is, neuroblastoma, ovarian, lung and mammary cell carcinoma) may be evaluated in the dog model with reduced-intensity conditioning to facilitate engraftment of chemoresistant MDR1-modified HSCs. Finally, the antifolate resistance gene variant, dihydrofolate reductase (DHFR(L22Y)), may be more useful in the context of transient expansion of DHFR(L22Y)-modified allogeneic T cells and in the elimination of unmodified T lymphocyte populations to facilitate engraftment of allogeneic HSCs early after transplantation.

In conclusion, these results demonstrate that reduced-intensity BCNU/TMZ conditioning coupled to lentivirus-mediated gene transfer of MGMT(P140K) into autologous HSCs supports in vivo selection, O6BG/TMZ post-transplant dose escalation that may be translated to a clinical setting in support more aggressive treatment, and possibly extend survival in patients suffering from GBM. Furthermore, the lessons learned from this model of reduced-intensity chemical conditioning and drug resistance gene transfer may be extrapolated for use in other drug resistance chemotherapy platforms, for the treatment of other malignancies and for potential use in alternative therapeutic applications.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

We thank Helen Crawford, Laura Farren and Bonnie Larson for help in preparing this manuscript. We also thank Michele Spector and the Fred Hutchinson Cancer Research Center Dog Lab staff for the care of the dogs. This work was supported in part by National Institutes of Health (Bethesda, MD) grants P01HL036444, RO1HL74162 and P30DK056465. H-FK is a Markey Molecular Medicine Investigator and the recipient of the Jose Carreras EDS Thomas Endowed Chair for Cancer Research. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health nor its subsidiary Institutes and Centers.

REFERENCES

1. Neff T, Beard BC, Kiern H-P. Survival of the fittest: in vivo selection and stem cell gene therapy (Review). Blood 2006; 107: 1751–1760.
2. Beard BC, Trobridge GD, Ironside C, McCune JS, Adair IE, Kiern H-P. Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates. J Clin Invest 2010; 120: 2345–2354.
3. Beard BC, Sud R, Keyser KA, Ironside C, Neff T, Gerull S et al. Long-term polyclonal and multilineage engraftment of methylguanin methyltransferase P140K gene-modified dog hematopoietic cells in primary and secondary recipients. Blood 2009; 113: 5094–5103.
4. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009; 326: 818–823.
5. Aiuti A, Cassani B, Andolfi G, Mirolo M, Biasco L, Recchia A et al. Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. J Clin Invest 2007; 117: 2233–2240.
6. Ott MG, Schmidt M, Schwartzwaelder K, Stein S, Siler U, Koehl U et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by selective activation or MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006; 12: 401–409.
7. Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, De Villartay JP et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002; 346: 1185–1193.
8. Andion M, Molina B, Gonzalez-Vicent M, Alonso L, Hernandez C, Lassaletta A et al. High-dose busulfan and cyclophosphamide as a conditioning regimen for autologous peripheral blood stem cell transplantation in childhood non-Hodgkin lymphoma patients: a long-term follow-up study. J Pediatr Hematol Oncol 2009; 31: 326.
9. Gozdzik J, Pituch-Noworolska A, Skoczien S, Czogala W, Baran J, Krasowska-Kwiecien A et al. Allogeneic haematopoietic stem cell transplantation as therapy for chronic granulomatous disease-single centre experience. J Clin Immunol 2011; 31: 332–337.
10. Escalon MP, Stefanovic A, Venkatraman A, Pereira D, Santos ES, Goodman M et al. Autologous transplantation for relapsed non-Hodgkin’s lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience. Bone Marrow Transplantation 2009; 44: 89–96.
11. McCune JS, Batchelder A, Deeg HJ, Gooley T, Cole S, Phillips B et al. Cyclophosphamide followed targeting oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality. Biol Blood Marrow Transplant 2007; 13: 853–862.
Reduced-intensity conditioning in dogs

JL Gori et al

26 Chinnasamy N, Rafferty JA, Hickson I, Ashby J, Tinwell H, Margison GP et al. O6-benzylguanine potentiates the in vivo toxicity and clastogenicity of temozolo-

mide and BCNU in mouse bone marrow. Blood 1997; 89: 1566–1573.

27 Westerhof GR, Down JD, Blokland I, Wood M, Boudewijn A, Watson AJ et al. O6-

Benzylguanine potentiates BCNU but not busulfan toxicity in hematopoietic stem

cells. Exp Hematol 2001; 29: 633–638.

28 Friedman HS, Keir S, Pegg AE, Houghton PJ, Colvin OM, Moschel RC et al. O6-

benzylguanine-mediated enhancement of chemotheraphy. Mol Cancer Ther 2002;

1: 943–948.

29 Neff T, Horn PA, Peterson LJ, Thomasson BM, Thompson J, Williams DA et al. Methylguanine methyltransferase-mediated in vivo selection and chemoprotet-

ion of allogeneic stem cells in a large-animal model. J Clin Invest 2003; 112:

1581–1588.

30 Neff T, Beard BC, Peterson LJ, Anandakumar P, Thompson J, Kiem H-P. Polyclonal

chemoprotection against temozolomide in a large-animal model of drug resistance gene therapy. Blood 2005; 105: 997–1002.

31 Horn PA, Keyser KA, Peterson LJ, Neff T, Thomasson BM, Thompson J et al. Efficient lentiviral gene transfer to canine repopulating cells using an overnight transduction protocol. Blood 2004; 103: 3710–3716.

32 Goerner M, Horn PA, Peterson J, Kurre P, Storb R, Jel L et al. Sustained multilineage gene persistence and expression in dogs transplanted with CD34+
marrow cells transduced by RD114-pseudotype oncoretrovirus vectors. Blood

2001; 98: 2065–2070.

33 Neff T, Horn PA, Valli VE, Gown AM, Wardwell S, Wood BL et al. Pharmacologically

degraded in vivo selection in a large animal. Blood 2002; 100: 2026–2031.

34 Fischer A, Hacein-Bey-Abina S, Cavazzana-Calvo M. Gene therapy for primary

adoptive immune deficiencies. J Allergy Clin Immunol 2011; 127: 1356–1359.

35 Auci A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A et al. Correction of ADA-

SCID by stem cell gene therapy combined with nonmyeloablative conditioning.

Science 2002; 296: 2410–2413.

36 Boztug K, Schmidt M, Schwarzer A, Hubner RA et al. Gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med 2010; 363:

1918–1927.

37 Rattmann I, Kleff V, Sorg U, Bardenheuer W, Bruenecker H, Hilger RA et al. Gene

transfer of cytodieme deaminase protects myelopoeis from cytodieme analogs in an

in vivo murine transplant model. Blood 2006; 108: 2965–2971.

38 Budak-Alpdogan T, Alpdogan O, Banerjee D, Wang E, Moore MA, Bertino JR.

Methotrexate and cytarabine inhibit progression of human lymphoma in NOD/

SCID mice carrying a mutant dihydrofolate reductase and cytodieme deaminase

fusion gene. Mol Ther 2004; 10: 574–584.

39 de Cremoux P, Jourdan-Da-Silva N, Couturier J, Tran-Perennou C, Schleiermacher

G, Fehlbaum P et al. Role of chemotheraphy resistance genes in outcome of

neuroblastoma. Pediatr Blood Cancer 2007; 48: 311–317.

40 Martin LP, Schilder RJ. Management of recurrent ovarian carcinoma: current status

and future directions (Review). Semin Oncol 2009; 36: 112–125.

41 Stewart DJ. Tumor and host factors that may limit efficacy of chemotheraphy in

non-small cell and small cell lung cancer (Review). Crit Rev Oncol Hematol 2010;

75: 173–234.

42 Noguchi S. Predictive factors for response to docetaxel in human breast cancers (Review). Cancer Sci 2006; 97: 813–820.

43 McGrogan BT, Gilmartin B, Carney DN, McCann A, Taxanes, microtubules and chemoresistant breast cancer (Review). Biochim Biophys Acta 2008; 1785:

96–132.

Supplementary Information accompanies the paper on Cancer Gene Therapy website (http://www.nature.com/cgt)